Reuters -- An experimental hepatitis C treatment being developed by Anadys Pharmaceuticals Inc (ANDS.O) demonstrated impressive early response rates with no serious safety issues, according to preliminary data from a small mid-stage clinical trial.
Reuters -- An experimental hepatitis C treatment being developed by Anadys Pharmaceuticals Inc (ANDS.O) demonstrated impressive early response rates with no serious safety issues, according to preliminary data from a small mid-stage clinical trial.
